2-Ethoxy-1,1-diisocyanoprop-1-ene

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Ethoxy-1,1-diisocyanoprop-1-ene
• 化学式: C7H8N2O
• 分子量: 136.15
• InChiKey: KLIAXURKRGKNAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  18
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• BICYCLIC INHIBITORS OF ALK
  申请人：Vasudevan Anil

  公开号：US20140171429A1

  公开（公告）日：2014-06-19

  The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R 1 , R 2 , R 3 , X, Y, Z, A, B, G 1 , m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

  本发明涉及式(1)的化合物或药用可接受的盐，式(1)中R1、R2、R3、X、Y、Z、A、B、G1、m和n的定义在说明中。本发明还涉及含有所述化合物的组合物，用于抑制激酶如ALK以及治疗癌症等疾病的方法。
• HCV INHIBITING BI-CYCLIC PYRIMIDINES
  申请人：SIMMEN Alan Kenneth

  公开号：US20070155716A1

  公开（公告）日：2007-07-05

  The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.

  本发明涉及双环嘧啶作为HCV复制抑制剂的使用，以及它们在治疗或对抗HCV感染的药物组合物中的使用。此外，本发明涉及制备这种药物组合物的过程。本发明还涉及将本双环嘧啶与其他抗HCV药剂组合使用的方法。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：Buckman Brad O.

  公开号：US20130072449A1

  公开（公告）日：2013-03-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
• 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：SHEN Dong-Ming

  公开号：US20180134712A1

  公开（公告）日：2018-05-17

  The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
• US7223766B2
  申请人：——

  公开号：US7223766B2

  公开（公告）日：2007-05-29